Physician profile
Mark Radetic
NPI 1760915250
$6,399.97
in general payments reported to CMS, 2019-2025
19 companies · $2,238 in 2025
The $2,238 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $107 · 2022: $122 · 2023: $291 · 2024: $3,642 · 2025: $2,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,856 · Food and Beverage: $2,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,855.67 |
| Food and Beverage | $2,315.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $2,593.75 | 2024-2025 | Single Use Electrosurgical Knife Kd-655, Disposable Distal Attachment, Olympus |
| Wilson Cook Medical Incorporated | $884.06 | 2024-2025 | Fusion |
| Cook Medical LLC | $738.78 | 2024-2025 | Fusion |
| Medtronic, INC. | $668.25 | 2021-2024 | Endoflip, Nexpowder |
| Madrigal Pharmaceuticals | $270.62 | 2025 | Rezdiffra |
| 3-D Matrix, INC. | $188.66 | 2024 | |
| Gilead Sciences, INC. | $164.08 | 2024-2025 | Livdelzi |
| Janssen Biotech, INC. | $150.02 | 2024-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $124.66 | 2024-2025 | Voquezna |
| Abbvie INC. | $123.81 | 2024-2025 | |
| Merit Medical Systems INC | $120.80 | 2025 | Esophyx |
| Mallinckrodt Hospital Products INC. | $114.72 | 2025 | Terlivaz |
| Olympus America INC. | $86.36 | 2024 | Single Use Electrosurgical Knife Kd-655 |
| Boston Scientific Corporation | $56.31 | 2025 | Overstitch Endoscopic Suturing System |
| Aimmune Therapeutics, INC. | $30.12 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $23.67 | 2025 | Sutab, Suflave |
| Celltrion USA INC. | $22.23 | 2024 | Vegzelma |
| Amgen INC. | $19.77 | 2025 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $19.30 | 2025 | Eohilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Radetic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.